| 摘要 |
Producing (M1) a cellular allogeneic vaccine (I) based upon an allogeneic antigen presenting cells (APC) (II), involves isolating (II) from a subject, modifying (II) with an antigen using pulsing, transfection, infection or fusion, treating (II) with an agent capable of removing sialic acid on surface of (II) and optionally culturing the modified (II) a suitable medium. Producing (M1) a cellular allogeneic vaccine (I) based upon an allogeneic antigen presenting cells (APC) (II), involves: (a) isolating an (II) from a subject, preferably from a normal blood donor or a patient suffering from myeloid malignancies, or providing (II) already established and/or isolated from a myeloid leukemia cell line; (b) modifying (II) with an antigen using pulsing, transfection, infection or fusion; (c) treating (II) with an agent capable of removing sialic acid on the surface of (II) and optionally; (d) culturing the modified (II) a suitable medium. Independent claims are also included for the following: (1) a cellular allogeneic vaccine (III) obtainable by (M1); (2) a composition (IV) comprising (III) and a carrier; and (3) a frozen container comprising (IV). |
